Cargando…
Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination
1,2:5,6-Dianhydrogalactitol (DAG) is a bifunctional DNA-targeting agent causing N(7)-guanine alkylation and inter-strand DNA crosslinks currently in clinical trial for treatment of glioblastoma. While preclinical studies and clinical trials have demonstrated antitumor activity of DAG in a variety of...
Autores principales: | Zhai, Beibei, Steinø, Anne, Bacha, Jeffrey, Brown, Dennis, Daugaard, Mads |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170372/ https://www.ncbi.nlm.nih.gov/pubmed/30283085 http://dx.doi.org/10.1038/s41419-018-1069-9 |
Ejemplares similares
-
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells
por: Zhai, Beibei, et al.
Publicado: (2020) -
SPDR-01 INHIBITION OF HOMOLOGOUS RECOMBINATION, PARP INHIBITOR, OR DIANHYDROGALACTITOL OVERCOMES TEMOZOLOMIDE-RESISTANCE IN GLIOMA CELLS
por: Ohba, Shigeo, et al.
Publicado: (2019) -
Hepatoma-derived growth factor-related protein 2 promotes DNA repair by homologous recombination
por: Baude, Annika, et al.
Publicado: (2016) -
High-Frequency Homologous Recombination Occurred Preferentially in Populus
por: Geng, Xining, et al.
Publicado: (2021) -
Homologous Recombination Subpathways: A Tangle to Resolve
por: Elbakry, Amira, et al.
Publicado: (2021)